Company Profile
Aclaris Therapeutics Stock Price, News & Analysis
- Ticker:
- ACRS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
5.37 USD (+2.68%)
Close
Last updated: July 27, 2026
647M USD
Market cap
Why the stock is moving
As of Jul 27, 2026, ACRS closed up 2.68% at $5.37. No new same-company headline was identified in the current news window.
Company overview
Business overview
Aclaris Therapeutics is a dermatology and immunology company focused on inflammatory skin disease and immune-mediated disorders. Its story is built around targeted small-molecule and biologic programs.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Aclaris sits in specialty biotechnology.
Business Model Characteristics
The business depends on clinical data, pipeline prioritization, and whether the company can build a durable dermatology franchise.
Position Within the Biotechnology Landscape
Aclaris is a catalyst-sensitive dermatology and immunology name whose stock moves on data and pipeline clarity.
Future catalysts
Aclaris's catalysts are povorcitinib and zunsemetinib, especially in inflammatory skin disease where each update can change how investors view the immunology franchise. The company is still very much a data story.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
KYMR · Source: Kymera
- 02
- 03
- 04
- 05
Avalo Therapeutics to Participate in the BTIG Biotechnology Conference
AVTX · Source: Avalo Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Aclaris Therapeutics (ACRS)?
Aclaris Therapeutics (ACRS) most recently closed at 5.37 USD, a +2.68% move versus the previous session.
What is the market cap of Aclaris Therapeutics (ACRS)?
Aclaris Therapeutics currently has a market capitalization of 647M USD on BioPharmSignal.
What does Aclaris Therapeutics do?
Aclaris Therapeutics is a dermatology and immunology company focused on inflammatory skin disease and immune-mediated disorders. Its story is built around targeted small-molecule and biologic programs.
On which exchange is ACRS stock listed?
Aclaris Therapeutics (ACRS) is associated with NASDAQ, United States, Biopharma.
What is povorcitinib?
Aclaris's catalysts are povorcitinib and zunsemetinib, especially in inflammatory skin disease where each update can change how investors view the immunology franchise.
Which conditions is Aclaris Therapeutics targeting with povorcitinib?
Aclaris Therapeutics is associated with immunology, dermatology based on its company overview and current catalyst commentary.
How does Aclaris Therapeutics describe recent progress with povorcitinib?
Aclaris's catalysts are povorcitinib and zunsemetinib, especially in inflammatory skin disease where each update can change how investors view the immunology franchise.
What is zunsemetinib?
Aclaris's catalysts are povorcitinib and zunsemetinib, especially in inflammatory skin disease where each update can change how investors view the immunology franchise.